Pharma BD Deal Intelligence
AbbVie Inc. / Gubra A/S
2025 · Licensing/Option · $2.2B · Complete
AbbVie and Gubra announced a license agreement giving AbbVie global rights to develop and commercialize GUB014295, a long-acting amylin analog in Phase 1 for obesity. Gubra receives $350M in total upfront payments and is eligible for up to $1.875B in development, commercial and sales milestone payments, plus tiered royalties on global net sales.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Mar 03, 2025
- Deal value $2.2B
- Deal type Licensing/Option
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · AbbVie Inc. deals